Effect of sirolimus in the prevention of adhesions around intraabdominal prosthetic graft

World Journal of Surgery

Volumn 30, Issue 9, 2006, Pages 1648-1652

  Kanko, Muhip ^a   Ozbudak, Ersan ^a   Ozerdem, Ali ^a   Aksoy, Ahmet ^a   Kilic, Metehan ^a   Berki, K Turan ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

POLITEF; RAPAMYCIN;

ABDOMINAL AORTA; ABRASION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; CONFERENCE PAPER; CONTROLLED STUDY; HEALING; LAPAROTOMY; NONHUMAN; RAT; TISSUE ADHESION; TISSUE REACTION; VASCULAR SURGERY;

ABDOMEN; ADHESIONS; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CELL PROLIFERATION; IMMUNOSUPPRESSIVE AGENTS; POLYTETRAFLUOROETHYLENE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SIROLIMUS; TISSUE ADHESIONS;

EID: 33748766861     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-005-0750-1     Document Type: Conference Paper

References (30)

1. Gutmann J, Penzias A, Diamond MP. (1995) Adhesions in reproductive surgery. In: Wallach E, Zacur HI editors Reproductive medicine and surgery Mosby, Missouri, pp 691-693.
2. Whawell SA, Vipond MN, Scott-Coombes DM, et al. Plasminogen activator inhibitor-2 reduces peritoneal fibrinolytic activity in inflammation. Br J Surg 1993;80:107-109.
3. Sehgal SN, Baker H, Vezina C. Sirolimus (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot 1975;28:727-731.
4. Morris RE. Sirolimus: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992;6:39-87.
5. Roque M, Reis ED, Cordon-Cardo C, et al. Effect of p27 deficiency and sirolimus on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest 2001;81:895.
6. Marx SO, Marks AR. The development of sirolimus and its application to stent restenosis. Circulation 2001;104:852-855.
7. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
8. Sousa JE, Costa MA, Abizaid A, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.
9. Linsky CB, Diamond MP, Cunningham T, et al. Adhesion reduction in a rabbit uterine horn model using an absorbable barrier, TC-7. J Reprod Med 1987;32:17-20.
10. Naylor AR, Ah-See AK, Engeset J, et al. Graft occlusion following aortofemoral bypass for peripheral ischaemia. Br J Surg 1989;76:(6) 572-575.
11. Holmdahl L. Making and covering of surgical footprints. Lancet 1999;353:(9163) 1456-1457.
12. Hendrikx M, Mees U, Hill AC, et al. Evaluation of a novel synthetic sealant for inhibition of cardiac adhesions and clinical experience in cardiac surgery procedures. Heart Surg Forum 2001;4:(3) 204-210.
13. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg 1996;183:297-306.
14. Bakkum EA, Van Blitterswijk CA, Dalmeijer RAJ, et al. A semiquantitative rat model for intraperitoneal postoperative adhesion formation. Gynecol Obstet Invest 1994;37:99-105.
15. Buckman RF, Woods M, Sargent L, et al. A unifying pathogenetic mechanism in the etiology of intraperitoneal adhesions. J Surg Res 1976;20:(1) 1-5.
16. Holmdahl L, Al-Jabreen M, Xia G, et al. The impact of starch powdered gloves on the formation of adhesions in rats. Eur J Surg 1994;160:257-261.
17. Belluco C, Meggiolaro F, Pressato D. Prevention of post-surgical adhesions with an autocrosslinked hyaluronan derivative gel. J Surg Res 2001;100:217-221.
18. Wiseman DM, Haung WJ, Johns DB, et al. Time-dependent effect of tolmetin sodium in rabbit uterine adhesion model. J Invest Surg 1994;7:527-532.
19. Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interactions of cyclosporine and sirolimus to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-239.
20. Tu Y, Stepkowski SM, Chou T-C, et al. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995;59 :(2) 177-183.
21. Knight R, Ferraresso M, Serino F, et al. Low-dose sirolimus potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:(4) 947-949.
22. Ferraresso M, Tian L, Ghobrial R, et al. Sirolimus inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate longterm survival of heart allografts in rats. J Immunol 1994;153:(7) 3307-3318.
23. Segal SN, Camardo JS, Scarola JA, et al. Sirolimus (Sirolimus, rapamune). Curr Opin Nephrol Hypertens 1995;4:482-487.
24. Molnar-Kimber KL, Rhoad A, Warner L, et al. Evidence that the anti-tumor and immunosuppressive effects of sirolimus are mediated via similar mechanisms. Cold Spring Harbor Meeting on Cell Cycle, 18-22 May 1994. New York, Cold Spring Harbor Laboratory, 1994, p 141.
25. Schachner T, Zou Y, Oberhuber A, et al. Local application of sirolimus inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 2004;77:1580-1585.
26. Schatz RA, Penn IM, Baim DS. Stent restenosis study (STRESS): analysis of in-hospital results [abstract]. Circulation 1993;88:(Suppl I) 1-594.
27. Roque M, Cordon-Cardo C, Fuster V, et al. Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis 2000;153:315-322.
28. Suzuki T, Kopia G, Hayashi S-I , et al. Stent based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
29. Fukuda D, Sata M, Tanaka K, et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005;111:926-931.
30. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-89.